Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06493799
PHASE3

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Sponsor: Green Cross Wellbeing

View on ClinicalTrials.gov

Summary

Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)

Official title: A Multicenter, Randomized, Open-label, Active-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Drop of 'LAENNEC INJ. (Human Placenta Hydrolysate) Compared With Subcutaneous Injection in Patients With Chronic Liver Disease

Key Details

Gender

All

Age Range

19 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

226

Start Date

2024-07-01

Completion Date

2026-09-30

Last Updated

2026-02-25

Healthy Volunteers

No

Interventions

DRUG

LAENNEC (Human Placenta Hydrolysate) IV

Intravenous Injection

DRUG

LAENNEC (Human Placenta Hydrolysate) SC

Subcutaneous Injection

Locations (1)

GC wellbeing

Yongin-si, South Korea